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Abstract 
Background: The microbiota colonizing the gastrointestinal tract have been associated with both gastrointestinal 
and extra-gastrointestinal diseases. In recent years, considerable interest has been devoted to their role in the devel-
opment of neurologic diseases, as many studies have described bidirectional communication between the central 
nervous system and the gut, the so-called “microbiota-gut-brain axis”. Considering the ability of probiotics (i.e., live 
non-pathogenic microorganisms) to restore the normal microbial population and produce benefits for the host, their 
potential effects have been investigated in the context of neurologic diseases. The main aims of this review are to 
analyse the relationship between the gut microbiota and brain disorders and to evaluate the current evidence for the 
use of probiotics in the treatment and prevention of neurologic conditions.
Discussion: Overall, trials involving animal models and adults have reported encouraging results, suggesting that 
the administration of probiotic strains may exert some prophylactic and therapeutic effects in a wide range of neuro-
logic conditions. Studies involving children have mainly focused on autism spectrum disorder and have shown that 
probiotics seem to improve neuro behavioural symptoms. However, the available data are incomplete and far from 
conclusive.
Conclusions: The potential usefulness of probiotics in preventing or treating neurologic diseases is becoming a topic 
of great interest. However, deeper studies are needed to understand which formulation, dosage and timing might 
represent the optimal regimen for each specific neurologic disease and what populations can benefit. Moreover, 
future trials should also consider the tolerability and safety of probiotics in patients with neurologic diseases.
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Background
In recent years, the gut microbiota residing in the gas-
trointestinal tract have emerged as a topic of great inter-
est in medical research. The gut microbiota consist of 
trillions of microorganisms representing many different 
species of known bacteria, as well as viruses, fungi, pro-
tozoa and archaea [1, 2]. Among the various bacteria, the 
most abundant phyla are Bacteroidetes and Firmicutes, 
followed by Proteobacteria and Actinobacteria, while 
Fusobacteria and Verrucomicrobia are less common. 
Butyrate-producing bacteria and lactic acid bacteria are 
thought to have beneficial effects to the host through 
anti-inflammatory, anti-tumourigenic and pathogen-
exclusion properties [3].
The deep influence of the gut microbiota on human 
health and homeostasis has many clinical manifesta-
tions. Studies have shown how dysbiosis (i.e., a disrup-
tion of the balanced composition of the gut microbiota) 
is associated with gastrointestinal [4–7] and extra-gas-
trointestinal diseases [8–10]. Moreover, recent investiga-
tions have also advocated a possible role for microbiota 
in the pathogenesis of several brain disorders [11–13]. 
The emerging idea of the microbiota as a modulator of 
neural physiology has recently been investigated through 
the concept of the “microbiota-gut-brain axis”, which rep-
resents a composite model of interaction between the 
intestinal microbes and the brain. Despite the evidence of 
Open Access
Journal of 
Translational Medicine
*Correspondence:  susanna.esposito@unimi.it 
Pediatric Highly Intensive Care Unit, Department of Pathophysiology 
and Transplantation, Università degli Studi di Milano, Fondazione IRCCS 
Ca’ Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, 
Italy
Page 2 of 11Umbrello and Esposito  J Transl Med  (2016) 14:298 
such communication, the effect, magnitude and clinical 
relevance of the disruption of the microbiota in neuro-
logic diseases have yet to be clearly elucidated.
In view of these considerations, the potential role of 
probiotics in the prevention and treatment of neuro-
logic diseases presents an attractive possibility. Probiot-
ics are living non-pathogenic microorganisms that confer 
a health benefit and improve physiological conditions 
in the host when administered in adequate amounts, 
as a food ingredient, supplement or drug [14]. Probiot-
ics are mainly composed of lactic-acid bacteria, such as 
Lactobacilli, Lactococci and Bifidobacteria or yeasts as 
Saccharomycetes; to date, Lactobacillus rhamnosus GG, 
Lactobacillus casei, Lactobacillus plantarum, Lactobacil-
lus johnsonii, Bifidobacterium and Saccharomyces bou-
lardii are the most widely studied strains [15].
Although the exact mode of action of probiotics 
remains uncertain, it is likely that several mechanisms 
operate together. Probiotics exert a microbiological func-
tion by preventing opportunistic pathogens from occu-
pying functional niches in the gut microbial community, 
blocking epithelial attachment of pathogenic bacteria, 
inhibiting their growth with the production of lactic acid, 
propionic acid, acetic acid, bacteriocins and reactive 
oxygen species [16–19]; they also play a nutritional role 
by producing several vitamins, lactase and health-pro-
moting compounds [16–19]. In addition, they regulate 
intestinal transit and reinforce the gut barrier. Further-
more, probiotics play an important role in the regula-
tion of both the innate and adaptive immune systems by 
activating macrophages, NK cells and cytotoxic T cells, 
modulating the production of IgA, stimulating toll-like 
receptors and modifying the cytokine-expression profile 
[16–19].
Some differences in biological properties and clinical 
effects have been reported among the various probiotic 
strains, mainly caused by genetic diversity and host-bac-
teria interactions [20]. A great deal of evidence has estab-
lished that the effects of probiotics may be genus-specific 
and even species- or strain-dependent [21–23] and that 
their efficacy is influenced by the dose [24]. Moreover, 
there are differences even between single- and multi-
strain probiotic formulations; however, it is not clear 
whether supplementation with mixtures is better than 
using a single strain. On examination of 16 comparative 
studies, probiotic combinations appeared to be more 
effective than single components taken alone in 12 cases 
(75 %) [25], although in many studies, this comparison is 
biased because of differences in dose. It is possible that 
the presence of a wide variety of probiotic genera in a 
multi-strain preparation leads to lower efficacy because 
of mutual inhibition by different species. However, there 
are data supporting the idea that mixtures have superior 
effectiveness over single strains, possibly because of a 
greater concentration of probiotics, a broader range of 
action and synergistic effects [26].
Probiotics are used as an adjuvant therapy for many 
paediatric gastrointestinal and extra-intestinal diseases, 
but few data are available on their use in brain disorders. 
The main aims of this review are to analyse the relation-
ship between the gut microbiota and brain disorders and 
to evaluate the current evidence for the use of probiot-
ics in neurologic conditions. Particular attention is paid 
to factors that condition the modification of the gut 
microbiota and the possibility of managing neurologi-
cal diseases by modifying the gut microbial composition. 
PubMed was used to search for all of the studies pub-
lished over the last 15 years using the key word “microbi-
ota” and “gut” or “intestinal” and “nervous system”. More 
than 350 articles were found, and only those published in 
English and providing data on aspects related to neuro-
logic diseases were included in the evaluation.
Discussion
The microbiota‑gut‑brain axis
Accumulating evidence has shown that gut microbi-
ota influence human brain development and function 
[27–30]. The exchange of regulatory signals through an 
integrative, bidirectional communication between the 
gastrointestinal tract and the central nervous system rep-
resents the gut-brain axis [31, 32]. In this relationship, 
the gut microbiota play a pivotal role. This complex sys-
tem acts via direct and indirect mechanisms that involve 
neural, hormonal and immunological pathways [33–35].
In top-down signalling, the central nervous system 
influences the gut microbiota, mainly through the auto-
nomic nervous system and the hypothalamus–pituitary–
adrenal axis. Indeed, several studies have demonstrated 
that a stressful event, especially early in life, can disrupt 
the microbiota profile, limit its richness and diversity, 
and affect bacterial species [36–40], inducing a shift in 
microbial composition that may promote the transloca-
tion of species known to induce inflammation, such as 
Clostridia, and reduce the proportion of anti-inflamma-
tory bacteria, such as Lactobacillus.
Another pathway that can produce effects on the brain 
and behaviour involves the vagus nerve [41]. The modu-
lation of the gut microbiota using Lactobacillus rham-
nosus stimulated the transcription of γ-aminobutyric 
acid (GABA) receptors and induced behavioural and 
psychological responses with marked dependence on 
vagal integrity [42]. However, vagus-independent mecha-
nisms are involved as well [33]. The intestinal microbiota 
has a profound influence on several neurotransmitters 
and neuromodulators, such as monoamines, serotonin, 
GABA, and brain-derived neurotrophic factor [43–46], 
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which deliver signals to the brain trough enteric nerves, 
enterochromaffin cells [27] and the systemic circulation, 
crossing the blood–brain barrier [34], whose permeabil-
ity appears to be regulated by the microbiota in experi-
mental models [47].
Moreover, the gut microbiome induces maturation 
of the host immune system, contributes to establish-
ing a durable immune repertoire and modulates the 
innate and adaptive immune systems to support the 
dominance of regulatory networks that prevent inflam-
mation or immune-mediated disease and inflamma-
tory responses [48, 49]. In addition, microbiota protect 
the intestinal barrier by improving epithelial tight junc-
tions, thus reducing gut permeability; in fact, a damaged 
intestinal wall can lead to increased translocation of gut 
bacteria into the mesenteric lymphoid tissue, provoking 
immune and inflammatory responses and activating the 
vagus nerve and spinal afferent neurons. Inflammatory 
cytokines and the vagal system, in turn, affect the activ-
ity of the central nervous system, altering its function 
[50]. Interestingly, recent data reported the activation of 
inflammasomes—systems involved in the regulation of 
inflammatory responses through the production of pro-
inflammatory cytokines in children with ASD, suggest-
ing a possible new link between impaired gastrointestinal 
permeability and neuroinflammation [51].
Neural pathways originate in utero and continue to 
develop in early postnatal life [52]. It has been shown 
that the prenatal and postnatal early-life periods are 
both dynamic and vulnerable windows for brain devel-
opment. During these important neurodevelopmental 
phases, essential processes and structures are established. 
Exposure to adverse events that interfere with this criti-
cal sequence of events confers a high risk for the subse-
quent emergence of mental illness later in life [52]. It is 
increasingly accepted that the gastrointestinal microbiota 
contributes substantially to shaping the development of 
the central nervous system. Conversely, several studies 
have shown that early-life events can also impact on this 
gut community [52]. Due to the bidirectional communi-
cation between the gut and the brain, it is possible that 
aberrant situations affecting either organ in early life can 
impact on the other. Studies have now shown that devia-
tions from the gold standard trajectory of gut microbiota 
establishment and development in early life can lead not 
only to disorders of the gastrointestinal tract but also 
complex metabolic and immune disorders. Moreover, 
the gut microbiome, too, undergoes dramatic dynamic 
changes during growth, especially throughout infancy 
and childhood [53]. Metagenomic studies suggest that 
the microbiome may also evolve later, as adolescents 
have significantly different microbiota from adults [54]. 
Because maturation of the brain and microbiota appears 
to be concomitant, occurring in parallel and during simi-
lar periods, the existence of a critical window during 
which microbiota can influence brain development and 
vice versa has been postulated [55, 56]. Preclinical studies 
on germ-free (GF) mice demonstrated that abnormalities 
in neural growth factors and altered behaviours could be 
normalized by conventional bacterial colonization occur-
ring early in life, supporting the idea of a developmental 
window for gut-brain interaction, where some effects 
are especially important in childhood [57]. Furthermore, 
according to a recent study, the disruption of microbiota 
with high doses of antibiotics from weaning onwards 
could alter brain development and behaviour despite 
the presence of normal gut microbiota in early postna-
tal life [58]. These data extend the time window during 
which perturbations of microbiome and dysregulation of 
gut microbiome-brain axis may influence brain health to 
adolescence and early adulthood.
Considering these interactions and the emerging role of 
microbiota as a key element of neural development and 
regulation, adverse changes in the microbiota may cause 
alterations in neural networks, affecting general and 
mental health. A disruption during dynamic periods such 
as childhood and adolescence could alter brain-gut com-
munication, increasing the risk of neurodevelopmental 
and other brain disorders later in life [56, 59]. Thus, early 
pre-weaning and childhood seem to be the critical ages 
for modulating the intestinal microbiota by avoiding dys-
biosis using probiotics to prevent neurologic disorders.
Microbiome disruption in neurologic diseases
The alteration of microbiota-gut-brain axis interactions 
has been advocated as a possible cause of some brain dis-
eases, including ASD, Parkinson’s disease (PD), multiple 
sclerosis (MS) and mood disorders [13, 60–62]. How-
ever, there is still little evidence regarding the underlying 
mechanisms responsible, and there is no consensus on 
the importance of intestinal dysbiosis in the pathogenesis 
of neurologic diseases.
Based on pre-clinical evidence, the microbiota have 
proved essential for the development of experimental 
autoimmune encephalomyelitis (EAE). GF mice did not 
develop EAE in a spontaneous model [63] or showed sig-
nificantly attenuated disease in an inducible model [64]. 
In addition, the depletion of commensal microflora with 
oral antibiotics significantly reduced the severity of EAE 
when compared to control mice treated with intraperi-
toneal antibiotics or treated with phosphate-buffered 
saline [65], whereas bacterial colonization of GF mice 
reestablished EAE susceptibility [63]. Furthermore, in 
amyotrophic lateral sclerosis transgenic mice, butyrate-
producing bacteria (Butyrivibrio fibrisolvens), Escheri-
chia coli, and Firmicus sp. were significantly reduced 
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compared to wild-type mice, providing evidence of dys-
biosis [66]; however, it is not known whether the altered 
microbiome plays an active role in neuromuscular degen-
eration in amyotrophic lateral sclerosis.
In studies performed on adults, a reduced percent-
age of Prevotellaceae was detected in stool samples of 
PD patients compared to controls [67], while a greater 
abundance of Enterobacteriaceae was positively associ-
ated with the severity of postural instability and gait-
difficulty symptoms. Another finding among patients 
suffering from PD compared to controls was an increased 
level of urinary indoxyl sulphate unrelated to the pres-
ence of constipation, which suggested that the intestinal 
dysbiosis has already occurred at the onset of the disease 
and thus possibly plays a role in PD pathogenesis [68]. 
Human studies have also been performed on patients 
with MS: despite the limited number of subjects, these 
studies overall found variations in microbiota bacteria 
that may play a role in the inflammatory process of the 
disease [69].
Most of the studies of children concern ASD. Despite 
agreement among researchers in describing several dif-
ferences in the composition of the microbiota between 
ASD children and healthy siblings or unrelated controls 
[70], the studies sometimes yielded contradictory results 
about the nature or amount of microbes involved [71].
Finegold et al. studied the faecal microflora of 33 chil-
dren with ASD using a pyrosequencing technique and 
found that patients with ASD compared to controls had 
a higher proportion of Bacteroidetes and Proteobacteria 
and a lower abundance of Firmicutes and Actinobacte-
ria (especially Bifidobacterium) [72]. These results are 
consistent with the results of other studies that reported 
lower levels of Bifidobacterium species in children with 
ASD [73, 74]. Other abnormalities in composition of the 
gut microbiota of ASD children included a significantly 
higher proportion of Bacteroides vulgatus [72], Sutte-
rella, Ruminococcus torques [75], and Desulfovibrio sp. 
[72, 76]. The latter has been proposed as an important 
bacterium in the pathophysiology of ASD [77].
Moreover, markedly lower percentages of Prevo-
tella, Coprococcus and unclassified Veillonellaceae were 
reported in ASD children with gastrointestinal disor-
ders compared to healthy controls, and these altera-
tions were related to the severity of ASD symptoms [78]. 
Furthermore, several studies showed a greater number 
of Clostridium species in the faecal samples of autistic 
children [79–82]. These data suggest the involvement of 
Clostridia in ASD pathogenesis, as the oral administra-
tion of vancomycin to children with ASD led to a regres-
sion of the typical symptoms. Because this antibiotic is 
not absorbed in the gastrointestinal tract and its spec-
trum of action covers Gram-positive bacteria such as 
Clostridium, it is possible that these microorganisms play 
a role in ASD development, especially as vancomycin dis-
continuation led to a reversion of ASD symptoms [83].
The composition of the microbiota has also been 
explored in children with relapsing-remitting MS [84]. 
Interestingly, a shorter time to relapse was significantly 
associated with a reduction in Fusobacteria (p =  0.001) 
an increase in Firmicutes (p  =  0.003) and the presence 
of Archaea euryarchaeota (p  =  0.037). After covariate 
adjustment, only the depletion of Fusobacteria remained 
significantly associated with relapse risk. These data 
require deeper investigation but underline a possible 
connection between disruption of the gut microbiota and 
MS relapse risk, thus identifying a potential new target 
for treatment.
Potential effects of probiotics in neurologic diseases
To date, there are neither guidelines nor clear indications 
for the use of probiotics to prevent or treat paediatric 
neurologic diseases. The current evidence on this subject 
is poor and partial; most of the studies are based on pre-
clinical research in animals, such as GF mice subjected 
to early-life gut modulation of the microbiota or exposed 
to specific probiotics [85–96], while only a few concern 
adult subjects [97–106], and even fewer involve children 
[107–110].
Pre‑clinical studies
Although the role of probiotics in neurologic disorders 
is a topic of recent interest, there are many pre-clinical 
studies in the literature (Table  1). Overall, these studies 
show potential effects of probiotics in treating neurologic 
diseases and describe the neural, immunological and 
metabolic pathways involved [107]. The mechanisms of 
action are still speculated and unclear, and the choice of 
strain, dose and timing appears arbitrary.
Lavasani et al. reported that a five-day course of 3 Lac-
tobacillus strains (L. paracasei DSM 13434, L. plantarum 
DSM 15312, L. plantarum DSM 15313) in mice devel-
oping EAE suppressed disease progression and reversed 
the established disease by down-regulating MOG-reac-
tive T-cells and shifting the dominant immune response 
from Th1 to Th2; interestingly, beneficial effects were not 
observed after the administration of a monostrain probi-
otic; only the three strains taken together yielded thera-
peutic effects [86].
In a more recent study, Kwon et  al. investigated the 
potential prophylactic and therapeutic effects of IRT5, 
a combination of Streptococcus thermophilus, Lacto-
bacillus reuteri, Bifidobacterium bifidum, Lactobacil-
lus acidophilus and Lactobacillus casei (1 ×  108 colony 
forming units [CFU] for each strain) in EAE mice [87]. 
Pre-treatment with oral administration of IRT5 starting 
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3  weeks before EAE induction significantly decreased 
the incidence of EAE compared to controls (roughly 45 
vs. 90 %; p < 0.001) and clinical scores (by approximately 
50 %; p < 0.001) and reduced infiltration and inflamma-
tion in the spinal cord. Furthermore, the use of probiotics 
in ongoing disease significantly inhibited the progres-
sion of EAE and was associated with milder symptoms, 
although it did not entirely suppress disease progres-
sion [87]. The effects of IRT5 have also been examined 
in murine models of experimental autoimmune myas-
thenia gravis (EAMG): IRT5 intake starting two weeks 
before EAMG onset and continuing until six weeks after 
induction significantly suppressed disease development, 
with lower clinical scores in treated mice compared to a 
placebo control group (mean clinical scores 0.93 vs. 1.8; 
p < 0.05) [88]. Thus, it seems that the prophylactic effects 
of probiotics are more prominent than the therapeutic 
ones, likely because of the greater difficulty of modulat-
ing already abnormally activated immune cells.
An interesting recent trial demonstrated that a two-
week pre-treatment with Clostridium butyricum (1 × 109 
CFU) in mice had neuroprotective effects against ischae-
mia/reperfusion injury; in fact, neurologic deficit scores, 
which were higher in ischaemia/reperfusion mice com-
pared to sham mice (p < 0.01), significantly decreased in 
treated mice (mean scores 3.5 vs. 2.5; p < 0.05) compared 
to the ischaemia/reperfusion group, possibly because of 
anti-oxidant and anti-apoptotic effects [89]. Other stud-
ies showed that probiotic administration may lead to 
anxiolytic effects [90] and improvements in memory and 
learning [91]. In this regard, Bifidobacterium longum 
1714 had a positive impact on cognition [92] and Bifi-
dobacteria infantis attenuated inflammatory immune 
responses and elevated serotoninergic precursors, evi-
dence of an antidepressant effect of some strains [93].
Pre-clinical studies have also investigated the potential 
of chronic administration of probiotics in animal models. 
One study evaluated the effect of a 6-month treatment 
with lactic-acid bacteria on the central nervous system of 
growing rats [85]. Interestingly, after two months, lactic-
acid bacteria administration decreased astrocyte reactiv-
ity by reducing S-100b and GFAP protein synthesis in the 
posterior areas of the brain hemisphere and affected the 
motor behaviour of rats, showing a possible effect in the 
prevention of neurologic diseases. Beneficial effects on 
astrocytes seemed to disappear, however, after a 6-month 
treatment. Thus, the authors recommended supplement-
ing the traditional treatment of neurologic diseases with 
Lactobacillus for only 2–4 months, speculating that pro-
longed consumption may not be effective because of 
adaptation in the immunological, gastrointestinal and 
nervous systems. These data were, however, obtained 
from experimental models, and the time to adaption 
to a probiotic treatment may be different in adults and 
children.
One of the most interesting studies of probiotics in 
paediatrics was performed by Hsiao et  al., who investi-
gated the effect of the oral administration of Bacteroides 
fragilis (1 × 109 CFU) in the maternal immune-activation 
model of ASD in mouse offspring [94]. They found that 
probiotic treatment improved anxiety-like, stereotyped, 
sensorimotor and communicative behaviours, suggesting 
that microbial modulating therapies may be an effective 
and safe treatment for ASD. Remarkably, these effects 
were not related only to B. fragilis, as Bacteroides the-
taiotaomicron administration also significantly improved 
abnormal behaviours, whereas Enterococcus faecalis 
had no effects, thus suggesting that some specificity is 
required in bacterial treatment.
Interestingly, a recent systematic review that included 
25 randomized, controlled trials performed in animals 
and 15 in humans showed that Bifidobacterium (i.e., B. 
longum, B. breve, and B. infantis) and Lactobacillus (i.e., 
L. helveticus, and L. rhamnosus), with doses between 
Table 1 Main neurologic effects of probiotics in pre-clinical studies
Authors Probiotic strains studied Main neurologic results
Lavasani et al. [86] L. paracasei DSM 13434, L. plantarum DSM 15312,  
L. plantarum DSM 15313
Suppression of progression of experimental autoimmune 
encephalomyelitis and reversion of established disease
Kwon et al. [87] S. thermophilus, L. reuteri, B. bifidum, L. acidophilus and  
L. casei
Suppression of the incidence and progression of experimental 
autoimmune encephalomyelitis
Chae et al. [88] S. thermophilus, L. reuteri, B. bifidum, L. acidophilus and  
L. casei
Suppression of experimental autoimmune myasthenia gravis
Sun et al. [89] C. butyricum Neuroprotective properties
Savignac et al. [92] B. longum 1714 Positive impact on cognition
Desbonnet et al. [93] B. infantis Increase in serotoninergic precursors
Ushakova et al. [86] Lactobacilli Decrease in astrocyte reaction and motor behaviours
Hsiao et al. [94] B. fragilis Improvement in anxiety-like, stereotyped, sensorimotor and 
communicative behaviours
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109 and 1010 CFU for 2 weeks in animals and 4 weeks in 
humans [95]. These probiotics showed efficacy in improv-
ing psychiatric disorder-related behaviors including anxi-
ety, depression, ASD, obsessive–compulsive disorder, 
and memory abilities, including spatial and non-spatial 
memory.
In addition, Callaghan et al. administered an early-life 
stressor (i.e., maternal separation) to infant male rats, 
and investigated the effects of this stressor on condi-
tioned aversive reactions in the rats’ subsequent infant 
male offspring [96]. They demonstrated, for the first 
time, longer-lasting aversive associations and greater 
relapse after extinction in the offspring of rats exposed to 
maternal separation (F1 generation), compared with the 
offspring of rats not exposed to maternal separation (F0 
generation). These generational effects were reversed by 
probiotic supplementation, which was effective as both 
an active treatment when administered to infant F1 rats 
and as a prophylactic when administered to F0 fathers 
before conception (i.e., in fathers’ infancy). These find-
ings have high clinical relevance in the identification of 
early-emerging putative risk phenotypes across genera-
tions and of potential therapies to ameliorate such gen-
erational effects.
Trials on human adults
Clinical trials performed on adults appear to confirm the 
results achieved in animal studies, suggesting a poten-
tial role for probiotics in the treatment of several neu-
rologic diseases (Table  2). Specific probiotics seem to 
have positive effects on human brain activity, including 
in healthy subjects. In fact, in a double-blind, placebo-
controlled, randomized trial on healthy volunteers, the 
oral administration of Lactobacillus helveticus R0052 and 
Bifidobacterium longum R0175 for 30  days significantly 
reduced psychological distress and urinary free cortisol 
level (p < 0.05) [97]. Likewise, in a randomized controlled 
clinical trial on healthy women, the intake of fermented 
milk containing Bifidobacterium animalis subsp. lac-
tis, Streptococcus thermophiles, Lactobacillus bulgaricus 
and Lactococcus lactis subsp. lactis for 4 weeks affected 
responsiveness to negative emotional stimuli by reduc-
ing the reactivity of a widely distributed network of brain 
areas to an emotional attention task (49  % cross-block 
covariance¸ p  <  0.004) containing affective, visceros-
ensory, and somatosensory cortices [98]. These results 
demonstrated that the fermented milk affected activity of 
brain regions that control central processing of emotion 
and sensation.
Interesting data have also been achieved from patients 
with neurologic disease. The oral administration of Lac-
tobacillus casei strain Shirota for 4  weeks in patients 
suffering HTLV-1 associated myelopathy/tropical spas-
tic paraparesis showed a trend towards improved motor 
function (p  =  0.157) and significantly decreased uri-
nary symptoms (p = 0.0085) and spasticity in the lower 
extremities (p  =  0.015), likely because of an important 
increase in NK cell activity [99]. Moreover, a two-month 
course of the same probiotic strain in patients with 
chronic fatigue syndrome led to a significant decrease in 
anxiety symptoms compared to controls (p = 0.01) [100].
Positive results were observed also in irritable bowel 
syndrome in a retrospective study based on the survey 
of patients records. Trimebutin or mebeverin + anxioli-
tics  +  probiotics were associated with the best impact 
on clinical symptoms mainly in patients with depression 
[101]. A recent review reported that probiotics appeared 
clinically and therapeutically relevant to a range of dis-
orders, including chronic fatigue syndrome, fibromyalgia, 
and restless legs syndrome [102].
On the contrary, the role of probiotic therapy in hepatic 
encephalopathy is controversial. A meta-analysis of four-
teen randomized controlled trials reported a significant 
improvement in minimal hepatic encephalopathy (odds 
ratio [OR] 3.91; confidence interval [CI] 2.25–6.80; 
p  <  0.0001), decreased hospitalization rates (OR 0.53; 
Table 2 Main clinical trials performed involving adults on the effects of probiotics on neurologic diseases
Authors Study design Main neurologic results
Messaoudi et al. [97] Double-blind, placebo-controlled, randomized trial on healthy 
volunteers treated with the oral administration of L. helveti-
cus R0052 and B. longum R0175 vs. placebo for 30 days
Reduced psychological distress and urinary free-cortisol level in 
probiotics arm
Tillisch et al. [98] Randomized controlled clinical trial on healthy women 
treated with fermented milk containing B. animalis subsp. 
lactis, S. thermophiles, L. bulgaricus and L. lactis subsp. lactis vs 
placebo for 4 weeks
Reduction in responsiveness to negative emotional stimulations 
in probiotics arm
Matsuzaki et al. [99] Prospective, uncontrolled treatment with L. casei strain Shirota 
for 4 weeks in patients suffering HTLV-1 associated myelopa-
thy/tropical spastic paraparesis
Improvement in motor dysfunction, urinary symptoms and 
spasticity in lower extremities
Rao et al. [100] Double-blind, placebo-controlled, randomized trial in patients 
with chronic fatigue syndrome treated with L. casei strain 
Shirota vs placebo for 2 months
Decrease in anxiety symptoms in probiotic arm
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CI 0.33–0.86; p  =  0.01) and decreased progression to 
overt hepatic encephalopathy (OR 0.40; CI 0.26–0.60; 
p < 0.0001) when probiotics were compared to no treat-
ment/placebo [103]. However, a Cochrane review did not 
find sufficient evidence to recommend the routine use of 
probiotic therapy in such patients because of a high risk 
of systematic and random errors in the trials, which over-
all showed a reduction in ammonia concentration after 
probiotic administration but no unequivocal effects on 
clinically relevant outcomes [104].
Trials on children
So far, only a few clinical studies about the use of probi-
otic strains for paediatric neurologic diseases have been 
published, and the majority involved children with ASD 
(Table  3). All studies share many limitations related to 
design, sample size, inclusion criteria and evaluation 
of clinical scores. Moreover, none was specifically per-
formed to determine differences in neurologic outcomes 
or recognize adverse effects of probiotic supplementation 
[105].
According to one case report, probiotic supplementa-
tion improved school records and attitude towards food 
in a 6-year-old child with ASD; moreover, discontinua-
tion of the intervention led to a regression of symptoms, 
which was reversed with the reintroduction of probiotics 
[106].
In a randomized, double-blind, placebo-controlled 
study, Lactobacillus plantarum WCFS1 (daily dose, 
4.5 × 1010 CFU) was administered to children with ASD 
from 3 to 16  years of age who were divided into two 
groups: group I received a placebo during the first feed-
ing period (3  weeks) and a probiotic during the second 
(3  weeks); vice versa for group II [108]. Behavioural 
effects were assessed through a standardized Develop-
ment Behaviour Checklist, which showed improve-
ment in disruptive antisocial behaviours, anxiety and 
communication problems (p < 0.05) in those treated with 
probiotics [108].
In a cohort study on 22 children (age range 4–10 years) 
with ASD, oral supplementation with Lactobacillus aci-
dophilus strain Rosell-11 for 2  months improved the 
ability to concentrate and fulfil orders, but did not affect 
behavioural responses to other people’s emotions or eye 
contact [109].
A recent interesting study in children at risk of neu-
rodevelopmental disorders is that of Pärtty et  al. [110], 
who performed a randomized trial on 75 infants fol-
lowed for 13  years, giving Lactobacillus rhamnosus GG 
to 40 subjects (53.3 %) for the first 6 months of life and 
a placebo to the other 35 (46.7 %). At the age of 13 years, 
6 out of 35 (17.1 %) children in the placebo group were 
diagnosed with ASD or attention-deficit/hyperactivity 
disorder (ADHD), but none in the probiotic group were 
(p = 0.008). These results suggest that early administra-
tion of Lactobacillus rhamnosus GG started four weeks 
before expected delivery could possibly reduce the risk 
of developing ADHD or ASD by mechanisms not nec-
essarily related to the composition of the microbiota, as 
no single constant component of or change in the micro-
biota was detected in children with neuropsychiatric dis-
orders compared to those without such disorders. These 
data represent an interesting preliminary achievement in 
this field, though they are far from conclusive.
The prophylactic effects of probiotic strains on neu-
rologic outcome have been investigated in a prospective 
study examining their efficacy in preventing Candida 
late-onset sepsis [111]. A total of 249 preterm infants 
were divided into three groups: one group (n = 83) sup-
plemented with Lactobacillus reuteri ATCC 55730 (5 
drops per day in an oil formulation, equivalent to 1 × 108 
CFU), one (n = 83) with Lactobacillus rhamnosus ATCC 
53103 (1 capsule per day, equivalent to 6 × 109 CFU) and 
the other (n = 83) with no supplementation. All infants 
Table 3 Main clinical trials performed involving children on the effects of probiotics on neurologic diseases
ASD autism spectrum disorder
Authors Study design Main neurologic results
Parracho et al. 
[108]
Randomized, double-blind, placebo controlled study in 
children with ASD 3–16 years old treated with L. plan-
tarum WCFS1 vs placebo for 3 weeks
Improvement of disruptive antisocial behaviours, anxiety and com-
munication problems in probiotic arm
Kaluzna-Czaplinska 
et al. [109]
Cohort study of children with ASD 4–10 years old treated 
with L. acidophilus strain Rosell-11 for 2 months
Improvement in their ability to concentrate and fulfil orders, with no 
impact on behavioural responses to other people’s emotions or 
eye contact
Partty et al. [110] Randomized trial on infants followed for 13 years, giving L. 
rhamnosus GG vs placebo for the first 6 months of life
At the age of 13 years, 6 out of 35 (17.1 %) children in the placebo 
group were diagnosed with ASD or attention-deficit/hyperactivity 
disorder, but none in the probiotic group were
Romeo et al. [111] Randomized trial in preterm infants treated with L. reuteri 
ATCC 55730 or L. rhamnosus ATCC 53103 or no supple-
mentation for 6 weeks
Higher incidence of suboptimal neurological scores in the control 
group than in both the probiotic groups at 1 year of age
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were treated for 6  weeks. A neurologic assessment was 
carried out at 1  year of age using the Hammersmith 
infant neurological examination showed a statistically 
significant higher incidence of suboptimal scores in the 
control group (n  =  24) than in both probiotic groups 
(p  <  0.05). Thus, probiotics may be effective in protect-
ing infants from neurologic damage due to sepsis by 
significantly reducing Candida gastrointestinal coloniza-
tion and reducing invasive infections, which were more 
frequent in the control group than in the groups treated 
with L. reuteri and L. rhamnosus (4 vs. 1) [111].
Controversies and future challenges for probiotic‑based 
treatment in patients with neurologic diseases
The use of probiotics in the treatment of neurologic dis-
eases as a routine additive therapy raises some questions.
First, as the positive effects on neurologic diseases are 
divergent and dependent on the probiotic strain, it is 
important to perform extensive studies to identify the 
most appropriate single strain or microbial mixture for 
each specific neurologic disease [107].
Secondly, probiotics, as the current definition states, 
need to be administered in adequate amounts. The rec-
ommended dose and the optimal duration of treatment 
have not been completely established; pre-clinical and 
clinical trials in neurologic diseases differ widely in com-
position, quantity and timing of probiotic administra-
tion. Unfortunately, while there are recommendations 
for probiotic formulation and dosage for the treatment 
of other clinical conditions [112], no study of ideal for-
mulation has been performed in patients with neurologic 
disorders.
In addition, research should focus on the identification 
of a target population for probiotic therapeutic interven-
tion, including the optimal age of the patient and phase of 
the disease.
There is concern also about the composition, quality 
and efficacy of commercially available probiotics. Indeed, 
probiotic formulations contain only a small amount of 
beneficial bacteria, usually less than 10 strains that are 
limited in diversity, unlike our highly variable gut micro-
biota. Additionally, obligate anaerobes are under-repre-
sented in available products, though they correspond to 
an important part of intestinal bacteria [113]. Moreover, 
a fatality due to contamination of probiotic supplementa-
tion highlighted some doubts about the quality of some 
products [114]. The ability of each strain and commer-
cialized product to remain viable and effective at a spe-
cific target site should also be considered.
Furthermore, most of studies on the effects of probiot-
ics are affected by several limitations and/or confound-
ing factors (i.e., small size sample, different therapies, 
short follow-up, different evaluation of bowel). Moreover, 
other investigations have displayed that once pathogenic 
dysbiosis sets in, probiotics have not proven to be effec-
tive and other interventions such as engineered bacteria 
could be considered [115].
Finally, an extremely important issue involves the tol-
erability and safety of probiotics in children with neuro-
logic conditions. There is considerable evidence on the 
safety of probiotics especially related to the use of lacto-
bacilli and bifidobacteria [116]. Although several studies 
demonstrated the safety of probiotics, some authors have 
recently called for more research with more clinical trials 
to identify adverse effects [117]. Two new cases of Lac-
tobacillus sepsis have been reported in newborns [118] 
and, although they are rare, previous cases have also been 
identified. One occurred in a 6-year-old child with cer-
ebral palsy, mental retardation, and a seizure disorder 
[119, 120]. While neurologic diseases are not among the 
known conditions associated with increased risk of pro-
biotic-induced sepsis, we cannot exclude the possibility 
that patients with severe neurologic conditions may be at 
greater risk of adverse effects.
Conclusions
The potential usefulness of probiotics in preventing or 
treating neurologic diseases is becoming a topic of great 
interest. However, a better understanding of their mecha-
nisms of action is required to attribute to them a role in 
improving neurologic manifestations or decreasing the 
incidence of neurodevelopmental disorders. So far, most 
of the research on this topic has focused on the mecha-
nisms of the microbiota-gut-brain axis and the best results 
were observed in children with ASD. A deeper investiga-
tion into the efficacy of probiotics in modulating these 
connections will help clarify the aetiopathogenesis of ASD 
and some other neurologic diseases and identify new pos-
sible targets on which to intervene. Pre-clinical studies 
suggest promising results, though these findings are not 
systematic and univocal, but human studies are still lim-
ited and not yet conclusive. Well-designed, randomized, 
controlled clinical trials are needed to confirm experi-
mental results and to identify the appropriate strain, dose 
and timing for probiotic intervention. Then, a deeper 
evaluation of safety and tolerability should be carried out 
in additional studies. However, further clinical research 
must be encouraged because of the potential impact on 
neurologic diseases, which are serious public health prob-
lems for which there is still no definitive therapy.
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